ArticleBMC infectious diseases2025
Temporal phylodynamics of Coxsackievirus A6 VP1 in Shenzhen (2022-2024).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHand, foot, and mouth disease (HFMD) remains a significant childhood infection in the Asia-Pacific region; however, the emergence of Coxsackievirus A6 (CVA6) since 2008 has reshaped its epidemiology. Despite extensive national surveillance, the evolutionary tempo-spatial dynamics of CVA6 in southern China remain poorly characterized. This study aimed to delineate the temporal phylodynamics of the CVA6 VP1 region in Shenzhen and identify lineage-defining mutations that may inform early-warning systems and control strategies.
methodsEpidemiological surveillance data (2022-2024) were integrated with VP1 sequences from 47 Shenzhen isolates and 465 global reference strains (1949-2024). Real-time RT-PCR was used to determine serotype composition. Bayesian relaxed-clock, SkyGrid, and discrete phylogeographic models were applied to reconstruct substitution rates, lineage turnover, and transmission routes. Amino acid variability was mapped onto the VP1 protein structure.
resultsAmong 195,951 notifiable disease cases, 11,427 (5.8%) were identified as HFMD, with seasonal peaks consistently observed in June and a maximum of 3,185 cases recorded in June 2023. CVA6 was detected in 30.9% of tested specimens and predominated in 2023 (64.6%). Root-to-tip regression showed a strong temporal signal (R² = 0.86), and the mean VP1 substitution rate was 4.78 × 10⁻³ substitutions/site/year (95% highest posterior density [HPD]: 4.39-5.16 × 10⁻³), with the estimated time to the most recent common ancestor (tMRCA) around 1945. All Shenzhen isolates belonged to genotype D3 and formed three temporally structured clades interspersed with isolates from various Chinese provinces, suggesting frequent interprovincial transmission and limited geographic clustering. SkyGrid analysis indicated a rapid expansion in the effective population size beginning in 2008, which stabilized after 2010. A total of 31 VP1 amino acid substitutions were identified; twelve (e.g., positions 5, 8, 10, 14, 32, 98, 160, 174, 194, 261, 279, 305) were fixed compared to the prototype strain Gdula, while six variable sites (e.g., S97N, N241D) were located in surface-exposed or BC-loop regions. Pairwise nucleotide distances among local strains were ≤ 6.7%, compared to 19.5-22.0% divergence from Gdula.
conclusionsGenotype D3 of Coxsackievirus A6 appears to be a significant contributor to seasonal HFMD peaks in Shenzhen, particularly in early summer. Its high evolutionary rate, rapid lineage turnover, and limited geographic structuring emphasize the importance of coordinated, cross-regional molecular surveillance. The study identifies 31 amino acid substitutions, including surface-exposed sites, which may indicate ongoing antigenic drift and potential immune escape. These findings underscore the need for high-resolution genomic surveillance, early-warning systems, and region-specific control measures for effective management of HFMD. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.